Phase 3 interim data showed the mRNA vaccine candidate generated a strong immune response against Influenza A; but failed to demonstrate it was at least as effective as an existing vaccine against Influenza B.
A new experimental mRNA-based vaccine could give a baseline level of immune memory against diverse flu strains: and thus might serve one day as a general preventative measure against future flu pandemics, according to researchers.
Moderna released what it deemed to be positive interim data from the phase 1 study of its quadrivalent flu vaccine, mRNA-1010, on Friday. But the markets were left underwhelmed.
Seasonal flu vaccines typically work 40-60% of the time, according to the US Centers for Disease Control and Prevention (CDC). An experimental recombinant protein nanoparticle vaccine that stimulates a strong immune response is hoping to address that...
Sanofi warns that the World Health Organization’s delayed strain selection will push back the date on which it delivers vaccines for the 2019-2020 flu season.
Mucosis has been awarded a Wellcome Trust grant of €3.7m ($4m) to help develop a Respiratory Syncytial Virus (RSV) vaccine using its intranasal delivery platform.
Influenza research completed just before the US banned ‘gain-of-function’ studies could help vaccine makers boost virus yields and accelerate production say scientists.
US government scientists told a House subcommittee on oversight and investigations on Tuesday that the six months production time necessary for flu vaccine manufacturers can create difficulties for health experts selecting the appropriate virus strains...
Novartis’ seasonal flu vaccine Fluad has been deemed safe by the Italian Medicines Agency (AIFA) after testing the two batches connected to over a dozen deaths.
Italy has suspended the use of Fluad despite Novartis saying no causal relationship has been established between its seasonal flu vaccine and three deaths.
French biotech Calixar has developed a tech platform process it says makes flu vaccines six times more effective in terms of immunogenicity than others on the market.
Over the next five years the vaccine industry will see an influx of transdermal and intradermal delivery systems, as well as other more innovative administration techs, according to a new study from Frost and Sullivan.
The US Department of Health and Human Services has awarded almost $40m (29m Euros) in contracts to four contract flu vaccine manufacturers as part of an effort to increase fill and finish capacity by 20%.
The US FDA approval of the new quadrivalent flu vaccine in June has not quite given manufacturers enough time to meet demand expectations, as production time can take up to about six months.
